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Standard cytotoxic treatments for neuroendocrine tumours have been associated with limited activity and remarkable toxicity. A
phase II study was designed to evaluate the efficacy, safety and pharmacodynamics of temsirolimus in patients with advanced
neuroendocrine carcinoma (NEC). Thirty-seven patients with advanced progressive NEC received intravenous weekly doses of
25mg of temsirolimus. Patients were evaluated for tumour response, time to progression (TTP), overall survival (OS) and adverse
events (AE). Twenty-two archival specimens, as well as 13 paired tumour biopsies obtained pretreatment and after 2 weeks of
temsirolimus were assessed for potential predictive and correlative markers. The intent-to-treat response rate was 5.6% (95% CI
0.6–18.7%), median TTP 6 months and 1-year OS rate 71.5%. The most frequent drug-related AE of all grades as percentage of
patients were: fatigue (78%), hyperglycaemia (69%) and rash/desquamation (64%). Temsirolimus effectively inhibited the
phosphorylation of S6 (P¼0.02). Higher baseline levels of pmTOR (phosphorylated mammalian target of rapamycin) (P¼0.01)
predicted for a better response. Increases in pAKT (P¼0.041) and decreases in pmTOR (P¼0.048) after treatment were associated
with an increased TTP. Temsirolimus appears to have little activity and does not warrant further single-agent evaluation in advanced
NEC. Pharmacodynamic analysis revealed effective mTOR pathway downregulation.
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Neuroendocrine carcinomas (NEC) comprise a family of neo-
plasms derived from the diffuse neuroendocrine system with a
wide range of morphologic, functional and behavioural character-
istics (Jensen and Doherty, 2005). Conventional chemotherapy has
not shown a significant activity in advanced NEC, except for islet
cell carcinomas (ICC) where streptozocin-based combinations
with either 5-fluorouracil or doxorubicin have produced partial
remissions in 40–60% of selected patients (Moertel et al, 1982;
Moertel et al, 1992). However, carcinoid tumours (CT) seem to be
quite chemo-resistant, with response rates of o10% and a median
5-year survival of 18% (Oberg, 2001). Alternative treatments
including a-interferon 2b and local hepatic therapies for isolated
metastases, such as hepatic arterial bland or chemo-embolisation,
resection and radiofrequency ablation, have not demonstrated
significant impacts on overall survival (OS).
The mammalian target of rapamycin (mTOR) is a serine–
threonine kinase that participates in the regulation of cell growth,
proliferation and apoptosis through modulation of cell cycle
progression (Vignot et al, 2005). Mammalian target of rapamycin
regulates initiation of cap-dependent translation by phosphoryla-
ting 4E-binding protein 1, releasing eukaryotic initiation factor
4E (eIF4E) to bind with eIF4G of the 4E initiation protein complex.
Mammalian target of rapamycin also modulates ribosomal
function by phosphorylating p70
S6 kinase which activates the
ribosomal protein S6 (Podsypanina et al, 2001). Signalling through
the PI3K/AKT/mTOR pathway leads to an increase in translation,
particularly of proteins regulating cell cycle progression and
metabolism. In cancer cells, aberrant activation of the pathway
may occur through increased signalling via growth factor
receptors, activating mutations/amplification of the pathway
kinases or by loss of the tumour suppressor protein PTEN. The
latter has been described in NEC (Wang et al, 2002). Temsirolimus
(sirolimus 42-ester 2,2-bis hydroxymethyl propionic-acid; CCI-
779) is a more water-soluble ester derivative of its parent
compound sirolimus, selected for development as an anticancer
agent based on its more favourable pharmaceutical characteristics
and superior therapeutic index. Temsirolimus has already been
tested in phase I and II trials with promising activity and good
safety profile (Atkins et al, 2004; Baselga et al, 2004; Raymond
et al, 2004; Chan et al, 2005). In phase I studies, rash and mucositis
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swere dose-limiting, and other adverse events (AE) observed
include eczematous reactions, dry skin, herpes-type lesions, mild
myelosupression, hypercholesterolaemia and hypertriglyceridemia
(Atkins et al, 2004; Baselga et al, 2004; Raymond et al, 2004).
The primary objective of this study was to examine the objective
response rate (ORR) of temsirolimus in patients with recurrent
or metastatic NEC. Secondary objectives were: (i) to assess drug
toxicity; (ii) to determine through pharmacodynamic evaluations
whether temsirolimus downregulates mTOR and modulates
elements of the PI3K/AKT/mTOR pathway and (iii) to associate
pretreatment molecular characteristics, and molecular changes
between paired tumour biopsies, with clinical outcome.
PATIENTS AND METHODS
Eligibility
Patients were eligible if they were 18 years of age or older and had
histologically or cytologically confirmed NEC of either carcinoid or
pancreatic ICC pathologies. Patients had to have documented
progressive metastatic disease within 6 months of study entry.
Previous chemotherapy, investigational agents, radioactive thera-
pies and/or radiation were allowed if completed 44 weeks before
study entry. Previous local therapy (e.g. bland or chemo-
embolisation) was allowed if completed 46 weeks before study
entry. Patients were required to have measurable disease, an ECOG
performance status p2, normal serum cholesterol and triglyceride,
adequate haematologic, hepatic, renal and cardiac functions and a
life expectancy of 43 months. Patients had to have tumour lesions
accessible for core biopsy, and must agree to undergo tumour
biopsy before and 2 weeks after initiation of temsirolimus.
Treatment
Temsirolimus at 25mg was administered as a 30-min intravenous
infusion on a weekly schedule. Four weeks of treatment were
considered as one cycle.
Assessment of toxicity
Adverse events were graded using the National Cancer Institute
Common Terminology Criteria for Adverse Events v3.0.
Dose modifications
Dose modifications of temsirolimus were based on haematologic
and non-haematologic toxicities at the time of every weekly dose.
Upon recovery of toxicity within a maximum delay of 3 weeks,
temsirolimus may be re-started with a dose reduction. Stepwise
dose modifications from 25 to 20, 15 and 10mg were allowed, but
doses once reduced cannot be re-escalated.
Response assessment
Radiological imaging was repeated every 8 weeks to assess for
tumour response until disease progression, completion of study
treatment or discharge of patient from study. Tumour responses
were evaluated according to standard RECIST criteria (Therasse
et al, 2000). Objective responses were confirmed by central
independent radiological review.
Correlative studies
Archival tissues Archival paraffin slides were stained for PTEN,
p53, pAKT, pS6 and pmTOR (phosphorylated mTOR) by
immunohistochemistry. Slides were pretreated and incubated with
primary antibody (Appendix 1), followed by biotin-conjugated
secondaries and HRP-Streptavidin labelling reagent (ID Labs Inc.,
London, Ontario, Canada). Two pathologists, who were blinded to
clinical outcome (M-ST. and SA-R), evaluated independently for
each marker: (i) the percentage of stained cells, which was
converted to a four-tiered system (0¼0; 1¼p10%; 2¼11–50%
and 3¼X51%), and (ii) the intensity of staining (0–3). The sum
of both values was the specimen’s score (range 0–6). The scores
from the two pathologists were then averaged. PTEN was scored as
either ‘lost’ or ‘retained’.
Computerised image analysis for paired tumour biopsies Tumour
biopsies taken before and after 2 weeks post-treatment with
temsirolimus were collected into 10% neutral buffered formalin,
fixed overnight and transferred in 70% ethanol for processing into
paraffin blocks. Four micrometre thick sections were cut onto
Surgipath x-trat slides. Slides were pretreated by either pepsin
digestion or microwave retrieval and then incubated in primary
antibody overnight inside a moist chamber (Appendix 1). This was
followed with Cy3- or Cy5-conjugated secondaries (Jackson
ImmunoResearch, West Grove, PA, USA) for immunofluorescence.
Paired biopsies were stained for pAKT, pS6, pmTOR and peIF4G.
Biopsy slides were imaged with a laser scanning TISSUEscope
(Biomedical Photometrics, Waterloo, Ontario, Canada) using 2mm
per pixel resolution. All images were analysed blinded using MCID
Elite software (Imaging Research Inc., St Catharines, Ontario,
Canada). A threshold was set to select for positive staining of a
specific marker of interest. Results were expressed as the
percentage of positively stained areas in square microns within
the tumour regions, and the staining intensity reported as mean
optical density (IOD) in grey levels.
Statistical analysis
The primary endpoint was objective tumour response rate
(complete response (CR) or partial response (PR)). Secondary
endpoints included toxicity, stable disease (SD) rate, response and
SD duration, time to progression (TTP) and OS. A two-stage phase
II design was used. The treatment combination would be assumed
to be inactive if the objective response was at most 5% and active if
it was at least 25%, with a¼0.05 and b¼0.10. After completion of
accrual of 15 evaluable patients to stage I, while no CR or PR was
observed, there were 10 patients who fulfilled the criteria for SD.
After plotting out patient’s pretreatment and post-treatment
tumour progression rate, it was observed that at least three out
of these 10 patients had a significant decrease in this parameter
after starting temsirolimus, along with improvement in their
disease-related symptoms. As a result of these findings, it was
hypothesised that temsirolimus may have antitumour activity in
this tumour type but possibly not reliably evaluated by conven-
tional RECIST criteria. The protocol was amended and additional
patients accrued to stage II.
The Kaplan–Meier method was used to estimate survival
outcomes. Time to progression was measured from the first date
a patient received study medication until the date of tumour
progression. Progression-free survival (PFS) was estimated from
the first date a patient received study medication until the date of
progression, or death; OS was measured from the first date a
patient received study medication until the date of death or last
date the patient was known to be alive.
Molecular marker levels before temsirolimus treatment and
their changes measured on study were investigated as predictors of
objective tumour response, TTP and OS, using Spearman rank
correlation coefficients and Cox proportional hazards regression.
All tests were two-sided and P-values of 0.05 or less were
considered statistically significant.
This study was a collaborative effort between three consortia, led
by the Princess Margaret Hospital Phase II Consortium. Local
institutional review board approvals were obtained at all
participating centres.
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Patients
A total of 37 patients were accrued to the study from January 2004
to July 2005. One patient did not receive any treatment owing to
progressive disease before treatment initiation and was consider-
able ineligible. Thirty-six patients received at least one dose of
temsirolimus and were evaluated for safety. Patient characteristics
are listed in Table 1.
Efficacy
Tumour response Two patients, one with CT and one with ICC,
achieved a confirmed PR. One of them progressed after 18 cycles
(11.4 months after first observation of PR) and the other came off
study owing to unrelated cardiac disease (4.5 months after first
observation of PR). A third patient had an unconfirmed PR at the
end of cycle 8 and discontinued therapy not owing to toxicity.
Twenty additional patients had SD of at least 2 months’ duration
and among these, 10 patients continued treatment beyond six
cycles. Ten patients progressed on temsirolimus without ever
achieving an objective response. Eight of these patients had
radiological evidence of disease progression, one had symptomatic
progression during cycle 1, and one patient died of disease before
end of cycle 2. Figure 1 shows the maximum percentage of target
tumour lesion(s) reduction compared to baseline as assessed by
the RECIST criteria, listed by individual study patients.
As serum markers such as chromogranin A or 5HIAA were not
mandated in this protocol and not collected in all patients, the
biochemical response could not be assessed.
The intent-to-treat response rate for the entire study cohort is
2/36¼5.6% (95% CI 0.6–18.7%) and tumour control (SDþPR)
rate is 23/36¼63.9% (95% CI 46.2–79.2%). Response outcomes
were similar between the CT and ICC histologies, with PR rates of
4.8 and 6.7%, respectively.
TTP Five patients remain on study and continue to receive
treatment as of January 2006. Of the 31 patients who have come off
treatment, the reasons for discontinuation were: PD (15),
symptomatic PD (four), death (one), physician discretion (two),
AE (seven) and patient withdrawal (two). Median TTP is estimated
to be 6.0 months (95% CI 3.7-not reached); 6-month progression-
free rate is estimated to be 48.1% (95% CI 33.0–70.1%) and 1-year
progression-free rate is estimated to be 40.1% (95% CI 23.8–
67.4%) (Figure 2).
Survival At the time of reporting, 11 patients have died. Median
follow-up on the 25 patients alive at last follow-up is 13.9 months
(range 2.8–22.6 months), minimum follow-up is 6.9 months.
Median OS has not been reached; 6-month survival rate is
estimated to be 91.6% (95% CI 82.9–100.0%) and 1-year survival
rate is estimated to be 71.5% (95% CI 57.1–89.5%) (Figure 3).
Patients with ICC appeared to have slightly better TTP and OS but
statistical comparisons were not made for this subgroup analysis
(Table 2).
Toxicity
Safety and tolerability data are available for 213 treatment cycles,
with a median number of four cycles delivered per patient (range
1–21), AE deemed by the investigator as at least possibly related to
Table 1 Patient characteristics
Patients N¼36
No. %
Age (years)
Median 56
Range 36–77
Sex
Female 21 58
Male 15 42
ECOG PS
01 6 4 4
11 9 5 3
21 3
Type of tumour
Carcinoid 21 58
Islet cell carcinoma 15 42
Prior treatment
Adjuvant chemotherapy 2 6
Palliative chemotherapy 21 58
Radiotherapy 5 14
Bland embolisation 4 11
Surgery 26 72
Octreotide 9 25
No. of prior chemotherapy regimens
01 4 3 9
19 2 5
27 1 9
33 8
43 8
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Figure 1 Maximal percentages of tumour reduction for target lesion(s)
by RECIST criteria (Note: some patients with PD progressed owing to new
or increasing non-target lesions, or by symptomatic progression).
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Figure 2 Time to progression for entire study cohort.
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are shown in Table 3. Overall, treatment with temsirolimus was
well tolerated. The most frequent AE of all grades, at least possibly
related to study treatment, were: fatigue (78% of patients; 53% of
cycles), hyperglycaemia (69% of patients; 54% of cycles) and rash/
desquamation (64% of patients; 50% of cycles). Severe AE that
were grade X3 and at least possible attribution were uncommon.
Seven patients developed pneumonitis considered as possibly
related to temsirolimus, three of whom required drug discontinua-
tion. Other observed AE include two patients who had grade 5
events. One died from a pneumothorax and bronchospasm in cycle
2 unlikely related to temsirolimus and the other died from
pulmonary embolism 5 days after removal from study, deemed to
be possibly drug related.
Pharmacodynamic analysis
Twenty-two patients had archival specimens evaluable for analysis
of baseline molecular markers. No significant association was seen
between any of the pretreatment markers tested (PTEN, p53, pS6,
pmTOR and pAKT) and tumour response, TTP or survival.
Despite being nonstatistically significant, the loss of PTEN
expression was associated with a trend towards a shorter TTP
(P¼0.07).
Paired baseline and post-treatment biopsies were obtained from
23 patients, and 13 paired-samples were evaluable. The best
responses of these 13 patients were one PR, eight SD, three PD and
one nonevaluable. Baseline expression levels of pAKT, pS6,
pmTOR and peIF4G were determined and compared with
expression levels following 2 weeks of treatment. Temsirolimus
effectively inhibited the phosphorylation of S6 (P¼0.02) (Figure 4)
and higher baseline levels of pS6 showed a trend towards being
predictive of a better response (P¼0.097). Higher baseline levels
of pmTOR were predictive of tumour response (P¼0.01).
Increases in the expression of pAKT (P¼0.041), and decreases
in pmTOR (P¼0.048) after 2 weeks on treatment, were associated
with an increased TTP.
A discrepancy was noted in the predictive abilities of pS6 and
pmTOR between freshly procured pretreatment specimens vs
paraffin-embedded archival specimens. However, only seven
patients had both archival specimens and pretreatment tumour
biopsies that were evaluable. Hence, statistical comparisons were
not performed.
DISCUSSION
Neuroendocrine carcinomas, generally subcategorised into CT and
ICC, often pursue an indolent clinical course. However, patients
ultimately will become symptomatic either as a result of increasing
tumour bulk or hormonal hypersecretion. Somatostatin analogues
have proven successful in ameliorating symptoms of the carcinoid
syndrome but its benefit in survival is unclear (Saltz et al, 1993).
Streptozocin and DTIC-based regimens have been tested with only
modest activity and may also be associated with significant toxicity
(Moertel and Hanley, 1979; Engstrom et al, 1984; Moertel et al,
1992; Bukowski et al, 1994; Rivera and Ajani, 1998; Cheng and
Saltz, 1999; Ramanathan et al, 2001; McCollum et al, 2004; Sun
et al, 2005). As conventional systemic approaches remain
insufficient and highly toxic, there is an obvious need for novel
therapies in this tumour population.
The intent-to-treat response rate of 5.6% and median TTP of 6.0
months observed in our study compares favourably with other
targeted therapies tested in this tumour population. A recently
reported phase II study of gefitinib in 96 patients with progressive
NEC (55 with CT and 42 with ICC) revealed a 6-month-PFS of 51%
for the former and 28% for the latter. However, objective responses
were only seen in one out of 40 patients (2.5%) in the CT group
(Hobday et al, 2005). A phase II study with the multi-targeted
tyrosine kinase inhibitor sunitinib involving 112 patients (41 CT
and 61 ICC), reported an ORR of 8.8%, with a median TTP of 40
weeks and a high percentage of SD (Kulke et al, 2005). Efficacy
varied by tumour histology with an ORR of 2% (1/41) among CT vs
13% (8/61) among ICC. In another phase II study where 44 patients
with CT were randomised to bevazucimab or pegylated interferon,
the former showed superior activity (4/22 vs 0/22 confirmed PR),
reduction in tumour perfusion and improvement in PFS at 18
weeks (96% vs 68%) (Yao et al, 2005). However, neither of these
two latter trials required evidence of progressive disease before
study entry, therefore the patient populations are likely different
from ours.
Regarding histology, in our study temsirolimus appears to be
slightly more active in ICC than in CT, as reported with other
therapies (Moertel and Hanley, 1979; Engstrom et al, 1984; Sun
et al, 2005; Kulke et al, 2006). While our small sample size
precludes any definitive conclusions, it is possible that CT and ICC
will manifest different sensitivities to different targeted agents, as
is the situation with cytotoxic agents.
Table 2 Efficacy outcomes by histology
Islet cell n¼15 Carcinoids n¼21
n (%) n (%)
Best response
PR 1 (6.7) 1 (4.8)
SD 9 (60.0) 12 (57.1)
PD 4 (26.7) 6 (28.6)
Non-evaluable 1 (6.7) 2 (9.5)
PR+SD 10 (66.7) 13 (61.9)
Time to progression
Median (months) 10.6 6.0
6-month (%) 51.6 45.3
1-year (%) 25.8 45.3
Overall survival
Median (months) Not reached Not reached
6-month (%) 93.3 90.5
1-year (%) 85.6 60.7
Status at last follow-up
Alive 11 (73.3) 14 (66.7)
Receiving treatment
2 (13.3) 3 (14.3)
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Figure 3 Overall survival for entire study cohort.
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for the first time in this patient population, that temsirolimus
effectively downregulates the phosphorylation of S6, and that
higher baseline levels of pS6 and pmTOR seem to predict for a
better response. These results are consistent with those reported by
Cho et al (2005) which analysed predictive markers of temsiro-
limus in advanced renal cell carcinomas, confirming the value of
pS6 (Cho et al, 2005). In this study, we have selected an antibody
against pmTOR (ser2448) with high specificity, and this may
explain the finding of pmTOR as a predictive marker of response.
Other interesting pharmacodynamic findings include the rising
trend in AKT phosphorylation noted after treatment with
temsirolimus. Two alternative pathways that induce AKT activa-
tion may explain this finding (Figure 5). RAPTOR (regulatory
associated protein of mTOR) and RICTOR (rapamycin-insensitive
companion of mTOR) are key partnering proteins which complex
with mTOR and modulate its functions. Activation of AKT through
the mTOR–RICTOR complex could explain our observation
(Hresko and Mueckler, 2005; Sarbassov et al, 2005). Additionally,
AKT phosphorylation has been described through a feedback loop
of the PI3K/AKT/mTOR pathway from the insulin-like growth
factor I receptor (IGF-IR) (O’Reilly et al, 2006). Further
pharmacodynamic analysis revealed a positive association between
increases in pAKT and decreases in pmTOR with a more
prolonged TTP. These exploratory findings require confirmation
with larger series. The evaluation of archival specimens searching
Table 3 Drug-related adverse events occurring in 410% of treatment cycles
Grade 1–2 Grade 3–4
Adverse event Patients n (%) Cycles n (%) Patients n (%) Cycles n (%)
Constitutional symptoms
Fatigue 28 (78) 112 (53) 0 (0) 0 (0)
Hematologic
Anaemia 21 (58) 111 (52) 1 (3) 1 (0.5)
Lymphopenia 19 (53) 112 (53) 1 (3) 2 (1)
Thrombocytopenia 18 (50) 61 (29) 1 (3) 1 (0.5)
Leukocytes 13 (36) 37 (17) 0 (0) 0 (0)
Metabolic
Hyperglycaemia 17 (47) 92 (43) 8 (22) 24 (11)
Hypercholesterolaemia 13 (36) 68 (32) 2 (6) 7 (3)
Hypertriglyceridaemia 15 (42) 58 (27) 1 (3) 1 (0.5)
ALT 15 (42) 71 (33) 2 (6) 3 (1)
AST 20 (55) 71 (33) 1 (3) 1 (0.5)
ALP 6 (17) 28 (13) 1 (3) 1 (0.5)
Hypoalbuminaemia 9 (25) 35 (16) 0 (0) 0 (0)
Hypophosphataemia 8 (22) 35 (16) 4 (12) 15 (7)
Creatinine 13 (36) 33 (15) 0 (0) 0 (0)
Gastrointestinal
Mucositis 26 (72) 71 (33) 0 (0) 0 (0)
Dysgeusia 10 (28) 47 (22) 0 (0) 0 (0)
Nausea 13 (36) 35 (16) 0 (0) 0 (0)
Diarrhoea 11 (30) 40 (19) 3 (9) 3 (1)
Constipation 10 (28) 28 (13) 0 (0) 0 (0)
Anorexia 13 (36) 31 (14) 0 (0) 0 (0)
Dermatologic
Rash (desquamation) 22 (61) 104 (48) 1 (3) 3 (1)
Rash (acneiform) 16 (44) 76 (36) 0 (0) 0 (0)
Dry skin 12 (33) 40 (19) 0 (0) 0 (0)
Pruritus 9 (25) 38 (18) 0 (0) 0 (0)
Pulmonary
Pneumonitis 7 (19) 35 (16) 0 (0) 0 (0)
Pre Post
pS6
Correlative markers 
Pre-treatment Post-treatment
200 m
Figure 4 Pre- and post-treatment liver biopsies. Tissue sections were
first immunofluorescence-labelled for S235/236-S6 ribosomal protein,
imaged, and then restained with H&E. The grey scale images of pS6 are
unenhanced, at original resolution.
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those patients with loss of PTEN. The discordance between the
results from the archival and the freshly procured pretreatment
specimens in our study could be due to differences in the genetic
profile of primary and recurrent/metastatic tumours; tumour
heterogeneity; and different protocols for specimen handling.
Differences in time and speed of tissue fixation after biopsy or
resection may significantly affect the phosphorylated states of
signalling molecules.
In conclusion, temsirolimus appears to have only modest
activity with a manageable toxicity profile in advanced NEC.
The results of this study do not warrant further investigation
of this drug as a single agent in this patient population. Evaluation
of temsirolimus, in combination with other targeted agents,
such as a multi-kinase inhibitor or an antiangiogenic compound,
should be considered. The loss of PTEN expression could
represent a poor prognostic marker for NEC. Pharmacodynamic
analysis in paired tumour biopsies reflected effective mTOR
pathway downregulation and identified possible predictive
factors. Evaluations in larger populations are needed to confirm
these findings.
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Appendix 1
Antibodies used for immunofluorescence and immunohistochem-
istry analysis.
Antibody Source Pretreatment Dilution IF/IHC
pAKT ser473 Cell Signaling Microwave 1:300 IF–Cy5 and IHC
peIF4G ser1108 Cell Signaling Microwave 1:200 IF–Cy5
pmTOR ser2448 Cell Signaling Microwave 1:400 IF–Cy5 and IHC
pS6RP ser235/236 Cell Signaling Pepsin 1:200 IF–Cy5 and IHC
p53 D07 Novo Castra Microwave 1:100 IHC
PTEN Cell Signaling Microwave 1:200 IHC
IF¼immunofluorescence; IHC¼immunohistochemistry.
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